#leadership

The mess we're in is because of incompetent leaders. They got their positions through connections, not skill. And it shows.

Micromanagement and fear tactics will continue... the main goal is to push people out and force them to quit. It is no secret what the management is doing, change people's roles to unrealistic expectations in order to save money and to make the company look profitable on paper so they could off load it to another buyer. For years they have refused to provide employees with a clear Job Description while they shout at every meeting that the role and expectations have changed. They are waiting for people to adjust into their new and force upon role so that they could use the legal claws to bypass liability for changing employee roles without their consent. This is unlawful and unethical. No wonder why people are not performing their best because nor only they dont have capable leaders, they feel like they are being conned by their leaders...

Well said, @x0+1kvzddfk0.

It's been a few weeks, but I've finally calmed down. When I first heard the news my body felt weak, I couldn't sleep because this visionary was gone.

To have these indefinite rolling layoffs going on already for a year and probably continuing for few more years. What a morally bankrupt leadership void of any care for their employees. Also notice how this repugnant disgusting selfish behavior has been normalized and everyone has accepted it as common and ordinary. But it's nothing like it.

Not sure I understand how this happened. I’ve only been here 5 years, but the Sport Research Lab seems to have crazy low morale. A lot of people are abusing the workplace complaints system to attack bosses and colleagues. It didn’t always seem like this. Now leadership is doing these silly culture exercises to try and solve this huge problem because everyone is afraid of being targeted by their own co-workers.

Is it like this in other departments? Because it’s really bad over here in NSRL.

In John’s Q2 results email he said, “We’ll need to embrace a market-based culture and continue executing against our 2026 priorities.”

That got me thinking… what exactly does “market-based” mean?

A market-based system generally means rewards and consequences are tied to performance. High performers create more value and are rewarded accordingly. Poor decisions and poor performance have consequences. Resources flow to what works, and what doesn’t work gets changed or terminated… That’s not how this place feels.

For employees, compensation isn’t meaningfully tied to individual performance. Top performers and average performers often receive very similar outcomes, while broad policies apply to everyone regardless of results.

And if we’re truly going to talk about a market-based culture, shouldn’t that standard apply at every level of the organization, including leadership?

A market-based culture shouldn’t just measure employees. It should measure strategies, capital allocation, recruiting, retention, culture, innovation, and long-term shareholder value.

The phrase “market-based” only has meaning if accountability flows both ways. Otherwise, it’s just another slogan.

Stankey seemed awfully confident during today’s ATG Live. After one solid quarter in a six-year tenure, the tone came across as more smug than self-aware, and the comments about employees didn’t exactly help.

Let’s see what next week brings after Verizon and T-Mobile report. One quarter doesn’t erase years of mixed results or settle the competitive picture.

If I were in his position, I’d spend less time taking victory laps and more time rebuilding trust with the employees who helped deliver the quarter in the first place.

All of you gloating over the 2% increase in stock price today, just keep in mind that the stock is still 33% lower than it was 15 years ago and pays out only 70% of the dividend. The stock has grown $1.50 since Stank became CEO and dividend has gone down. Certainly nothing to crow about. RTO destroyed a once great American company.

INVESTORS DUMP YOUR STOCK BUD. YOU NEED A NEW APPROACH.

I think the biggest surprise will be how many of the PL's everyone has been talking about on here are taking this themselves. I have gotten wind of names of people that have been approved and lots of VP's and Directors that have been around awhile are taking this as an opportunity to leave.

Something I had not considered.

Robin Vince announcing his appointment to the OpenAI board reads like peak corporate satire: the CEO of a bank whose employees publicly describe leadership as opaque, dismissive, and allergic to accountability is now helping steer the future of “responsible AI.”

Sadly, it’s almost poetic. At BNY, Vince champions AI as a “capacity creator,” which is a polite way of saying it helps leadership know more, move faster, and replace people more efficiently — a theme not lost on the thousands of workers and former workers posting their experiences on this forum.

His statement about deploying AI “responsibly, securely, and with strong governance” lands awkwardly when employees can’t even get responsible communication about layoffs, offshoring, or the never‑ending transformation cycle. And the part about AI benefiting “all of humanity”? BNY staff might settle for it benefiting even just a fraction of its workforce.

The real comedy is the humility act — Vince describing himself as “humbled and grateful” while employees describe him as absent, evasive, and increasingly disconnected from the reality inside his own institution.

If OpenAI truly wants to understand how AI impacts people, they’ve now got a board member whose own employees already feel like failed test cases.

How can someone who is so out of touch possibly guide humanity’s future while BNY employees can’t get straight answers during his entire tenure with the firm?

Eliza? . . . Eliza? . . . Can we get a little help here?!?!

Are we submitting questions or assuming that even with the format pivot we aren’t going to get real, honest answers to questions.

Personally, I hope people submit their toughest questions and demand accountability from MKW. It’s been a sh*t couple of years and that’s largely on him and the rest of leadership.

No rhyme or reason for the chosen: some long term tenured, some newer, but good at their jobs. That department was being hammered by senior leadership about meeting SLAs. They will regret it later when the staffing is needed later in the year. Why, Lord, oh why?

Just my opinion, but after the last organizational shake-up, I wouldn’t be surprised if history repeats itself.

One question I keep coming back to: A.C. championed the “ways of working” in the previous CXO organization. Has anyone objectively looked at whether those same approaches may have contributed to some of the challenges the organization faced?

Hopefully the new organization has a different outcome—but time will tell. 🍿

Matt Carr had an all hands yesterday. He said we need to move on from the laid off employees, was laughing the entire time and came off as an arrogant fat man. Not to mention, was complimenting women for looking good, super weird. There was a tornado warning alarm that went off and he dismissed it and kept the call going. He’s not fit for that job. What makes him a psychopath more than anything is that he promised no more lay offs but we all know that lay offs will continue. These “leaders” are clueless.

You should not feel disrespected. You should be grateful and eager to work hard with a song in your heart!

We are evolving our structure and operating model by aligning leadership and decision-making more directly to the needs of each business, while centralizing select capabilities that create value across the organization.

In a previous town hall, the senior executive who will not be named listened to the frustration of senior directors (plural) under him, as well as chat entries of attendees, on Teamworks which made them lose valuable talent.

The feedback is in unison: Teamworks is not worth the negative impact to employee's welfare and retention. In the end, this senior executive said "Don't worry about teamworks. So long as we don't see an average of five hours of work per day, it's fine."

Well his other cohort, another senior executive, has been going around in staff meetings pressuring managers to get tighter on Teamworks or else they themselves will get in trouble.

Same company (Hughes), two senior executives, two different perspectives on Teamworks.

Sr. leaders: why are you still here? Cash comp at the 66th percentile, equity that hasn't moved since 2020. You're being paid below market and told the difference is in the stock — the same stock that just spent six years proving it isn't. Anyone with an equal offer should already be gone. And if you're lucky enough to catch a severance package? Take it. It's the best-performing asset this company has issued in a decade.

The sales manager cowards have all awoken from their coffins and have been unearthed - they cannot handle the pressure from the CRO and are funneling down the pressure. New VP nice guy but dud and already rolling out day 0 day 1 day 30 day 90 forecasting methods starting August and he thinks this is going to fix the horrid decline of this abomination of a company. SRD Kb lost her marbles and never make her number once as rep or dir or SRd she fire so many reps and replace with all duds already selling nothing what a joke

they all are cowards now writing big AI gen threaten emails to engineers support staff sales everyone

these are all big joke ppl

cro is biggest joke the tech industry has ever seen nobody gives a rats a-s about him or his life story or troubles no one like you! Leave cro!

This will be interesting.. anyone else see the email? Wondering if this new person will be any better

Somehow, over last 10 years, especially since 2019 things have gone to sh-t. Now, you may say it's her and I'd agree but I think we have major problem stemming from the weak c-level lineup (and one layer below).

After spending 12 years at Meta, it's amazing to see how much Llama has become a colossal failure. Yann's a smart dude, BTW.

A Review of Regulatory Settlements, Corporate Governance, Financial Performance, Executive Compensation, and Leadership Accountability Under CEO Sarah London

Executive Summary

Centene Corporation has become one of the largest government-funded healthcare organizations in the United States, generating more than $150 billion in annual revenue while administering Medicaid, Medicare, Affordable Care Act Marketplace, TRICARE, and correctional healthcare programs across dozens of states.

Because the overwhelming majority of Centene's revenue originates from taxpayer-funded healthcare programs, the company operates under heightened public trust and regulatory expectations.

Over the past several years, Centene has experienced an extraordinary number of legal settlements, regulatory investigations, financial setbacks, organizational restructurings, shareholder lawsuits, and public controversies. While many of these matters began before Sarah London became Chief Executive Officer in March 2022, they continue to define the environment she now leads.

This report examines publicly available information regarding:

• Medicaid pharmacy settlements approaching $1 billion
• Federal cybersecurity enforcement actions
• Financial reporting failures and withdrawn earnings guidance
• Shareholder litigation
• Executive compensation
• Workforce reductions and outsourcing
• Corporate governance concerns
• Strategic acquisitions and divestitures
• Public policy implications for taxpayers

The purpose of this report is not to establish wrongdoing where none has been proven. Rather, it evaluates whether recurring events indicate broader governance, oversight, or accountability concerns deserving additional public examination.

# Section 1

## Company Overview

Centene Corporation is among the nation's largest managed care organizations.

Its principal business consists of administering publicly funded healthcare through contracts with federal and state governments.

Major business lines include:

• Medicaid
• Medicare Advantage
• Medicare Part D
• Affordable Care Act Marketplace plans
• TRICARE support services
• Behavioral health management
• Pharmacy benefit management
• Specialty healthcare services

Because most revenues originate from public programs, taxpayers ultimately finance a significant portion of Centene's operations.

This creates a higher expectation for:

• Financial transparency
• Regulatory compliance
• Accurate reporting
• Effective stewardship of public funds
• Ethical corporate governance

# Section 2

## Nearly One Billion Dollars in Medicaid Pharmacy Settlements

Perhaps no issue has affected Centene's public reputation more than the series of settlements involving allegations related to Medicaid pharmacy benefit management.

Beginning in 2021, state attorneys general and Medicaid agencies alleged that Centene subsidiaries improperly reported prescription dr-g costs or retained pharmacy-related savings that should have been returned to Medicaid programs.

States reaching settlements include:

• California
• Texas
• Ohio
• Florida
• Mississippi
• Washington
• Arkansas
• Kansas
• Louisiana
• New Hampshire
• New Mexico
• and numerous others.

Collectively, publicly reported settlements have approached approximately one billion dollars.

Although Centene generally denied wrongdoing and resolved these matters without admitting liability, the repeated nature of the settlements raises legitimate policy questions regarding:

• Internal financial controls
• Pharmacy oversight
• Compliance monitoring
• Executive supervision
• Board governance

A single settlement may represent an isolated disagreement.

Repeated settlements involving numerous states warrant broader public scrutiny.

# Section 3

## The Florida Settlement and Subsequent Political Controversy

Centene's Florida Medicaid settlement became significantly more controversial after approximately $10 million of settlement proceeds were directed to the Hope Florida Foundation.

Subsequent reporting found that funds distributed through the nonprofit later reached organizations involved in political advocacy.

The controversy primarily concerns decisions made by state officials rather than allegations that Centene directed political activity.

Nevertheless, the settlement became part of a broader debate regarding:

• Transparency
• Public accountability
• Government contracting
• Use of Medicaid settlement proceeds

Given Centene's continued participation in Florida's Medicaid program, the issue has generated substantial legislative attention.

# Section 4

## Federal Cybersecurity Settlement

In February 2025, Centene and Health Net Federal Services agreed to pay more than $11 million to resolve allegations under the False Claims Act involving cybersecurity compliance on the TRICARE contract.

According to the Department of Justice, the government alleged deficiencies including:

• Untimely vulnerability remediation
• Failure to fully implement required security controls
• Inaccurate compliance certifications

Although these allegations primarily involved conduct predating Sarah London's appointment as CEO, the settlement illustrates ongoing regulatory exposure affecting the organization.

# Section 5

## Financial Forecasting Failure

One of the defining events of Sarah London's leadership occurred during 2025 when Centene unexpectedly withdrew previously issued earnings guidance.

The company disclosed significant changes involving:

• Marketplace member health risk
• Medical expense projections
• Risk adjustment revenue
• Affordable Care Act enrollment assumptions

The resulting revision represented approximately a $1.8 billion impact.

Investors responded immediately.

Centene experienced one of the largest single-day declines in company history.

Billions of dollars in market value were erased.

The company later reported its first adjusted quarterly loss in more than a decade.

This event prompted serious questions regarding:

• Financial forecasting
• Executive oversight
• Internal reporting systems
• Actuarial assumptions
• Board supervision

# Section 6

## Shareholder Litigation

Following the withdrawal of guidance, multiple shareholder lawsuits were filed against Centene and senior executives.

The complaints generally allege that investors received overly optimistic information regarding:

• Financial outlook
• Marketplace performance
• Medical costs
• Revenue expectations

These allegations remain pending.

No court has determined liability.

Nevertheless, the litigation reflects a significant loss of investor confidence.

# Section 7

## Executive Compensation

Sarah London's publicly disclosed compensation has remained approximately $20 million annually.

Supporters argue that executive compensation reflects the complexity of managing one of America's largest healthcare organizations.

Critics note that this compensation coincided with:

• Stock price declines
• Workforce reductions
• Regulatory settlements
• Financial forecasting failures
• Organizational restructuring

The issue is not whether executive compensation is legally permissible.

The issue is whether executive pay appropriately reflects organizational performance and accountability.

# Section 8

## Workforce Reductions and Outsourcing

Centene has pursued substantial organizational restructuring.

Reported actions include:

• Workforce reductions
• Voluntary separation programs
• Office consolidations
• Divestitures
• Increased automation
• Expanded outsourcing

Reports also indicate that Centene entered into a technology agreement with Cognizant valued at more than $500 million and potentially approaching $1 billion.

The reported initiative emphasizes:

• Artificial intelligence
• Claims automation
• Customer service modernization
• Administrative efficiencies

Critics argue that simultaneous workforce reductions and increased outsourcing may negatively affect employee morale, institutional knowledge, and organizational stability.

# Section 9

## Leadership Accountability

Sarah London inherited many of Centene's legacy legal matters.

However, executive leadership ultimately bears responsibility for:

• Organizational culture
• Financial controls
• Regulatory compliance
• Strategic direction
• Public accountability

To date, there is no public evidence that Sarah London personally engaged in fraud or criminal misconduct.

The primary questions concern executive judgment, governance, operational oversight, and corporate performance rather than personal wrongdoing.

# Preliminary Conclusions

Based upon publicly available information, several recurring themes emerge.

1. Repeated Regulatory Exposure

Numerous settlements across multiple states suggest systemic compliance challenges rather than isolated disputes.

2. Financial Governance Concerns

The 2025 withdrawal of earnings guidance represents one of the most significant operational failures in recent company history.

3. Increasing Public Accountability

Because Centene receives substantial taxpayer funding, operational failures have implications extending beyond shareholders to state governments, beneficiaries, and taxpayers.

4. Leadership Performance

Sarah London's tenure has coincided with significant restructuring, operational modernization, and continuing legal challenges. Whether these actions ultimately strengthen the organization remains an open question that will be judged by future financial performance, regulatory compliance, and restored investor confidence.

## Areas Warranting Additional Review

Future investigation could examine:

• Board oversight of pharmacy benefit management practices.
• Internal audit findings before major settlements.
• Executive incentive compensation tied to quality, compliance, and financial performance.
• The impact of outsourcing and artificial intelligence on claims accuracy and member services.
• The adequacy of forecasting controls preceding the 2025 guidance withdrawal.
• Trends in state regulatory actions, corrective action plans, and sanctions involving Centene subsidiaries.
• Corporate governance practices compared with peer managed care organizations.

### Executive Summary

Centene Corporation has become one of the largest government-funded healthcare organizations in the United States, generating more than $150 billion in annual revenue while administering Medicaid, Medicare, Affordable Care Act Marketplace, TRICARE, and correctional healthcare programs across dozens of states.

Because the overwhelming majority of Centene's revenue originates from taxpayer-funded healthcare programs, the company operates under heightened public trust and regulatory expectations.

Over the past several years, Centene has experienced an extraordinary number of legal settlements, regulatory investigations, financial setbacks, organizational restructurings, shareholder lawsuits, and public controversies. While many of these matters began before Sarah London became Chief Executive Officer in March 2022, they continue to define the environment she now leads.

This report examines publicly available information regarding:

• Medicaid pharmacy settlements approaching $1 billion
• Federal cybersecurity enforcement actions
• Financial reporting failures and withdrawn earnings guidance
• Shareholder litigation
• Executive compensation
• Workforce reductions and outsourcing
• Corporate governance concerns
• Strategic acquisitions and divestitures
• Public policy implications for taxpayers

The purpose of this report is not to establish wrongdoing where none has been proven. Rather, it evaluates whether recurring events indicate broader governance, oversight, or accountability concerns deserving additional public examination.

# Section 1

## Company Overview

Centene Corporation is among the nation's largest managed care organizations.

Its principal business consists of administering publicly funded healthcare through contracts with federal and state governments.

Major business lines include:

• Medicaid
• Medicare Advantage
• Medicare Part D
• Affordable Care Act Marketplace plans
• TRICARE support services
• Behavioral health management
• Pharmacy benefit management
• Specialty healthcare services

Because most revenues originate from public programs, taxpayers ultimately finance a significant portion of Centene's operations.

This creates a higher expectation for:

• Financial transparency
• Regulatory compliance
• Accurate reporting
• Effective stewardship of public funds
• Ethical corporate governance

# Section 2

## Nearly One Billion Dollars in Medicaid Pharmacy Settlements

Perhaps no issue has affected Centene's public reputation more than the series of settlements involving allegations related to Medicaid pharmacy benefit management.

Beginning in 2021, state attorneys general and Medicaid agencies alleged that Centene subsidiaries improperly reported prescription dr-g costs or retained pharmacy-related savings that should have been returned to Medicaid programs.

States reaching settlements include:

• California
• Texas
• Ohio
• Florida
• Mississippi
• Washington
• Arkansas
• Kansas
• Louisiana
• New Hampshire
• New Mexico
• and numerous others.

Collectively, publicly reported settlements have approached approximately one billion dollars.

Although Centene generally denied wrongdoing and resolved these matters without admitting liability, the repeated nature of the settlements raises legitimate policy questions regarding:

• Internal financial controls
• Pharmacy oversight
• Compliance monitoring
• Executive supervision
• Board governance

A single settlement may represent an isolated disagreement.

Repeated settlements involving numerous states warrant broader public scrutiny.

# Section 3

## The Florida Settlement and Subsequent Political Controversy

Centene's Florida Medicaid settlement became significantly more controversial after approximately $10 million of settlement proceeds were directed to the Hope Florida Foundation.

Subsequent reporting found that funds distributed through the nonprofit later reached organizations involved in political advocacy.

The controversy primarily concerns decisions made by state officials rather than allegations that Centene directed political activity.

Nevertheless, the settlement became part of a broader debate regarding:

• Transparency
• Public accountability
• Government contracting
• Use of Medicaid settlement proceeds

Given Centene's continued participation in Florida's Medicaid program, the issue has generated substantial legislative attention.

# Section 4

## Federal Cybersecurity Settlement

In February 2025, Centene and Health Net Federal Services agreed to pay more than $11 million to resolve allegations under the False Claims Act involving cybersecurity compliance on the TRICARE contract.

According to the Department of Justice, the government alleged deficiencies including:

• Untimely vulnerability remediation
• Failure to fully implement required security controls
• Inaccurate compliance certifications

Although these allegations primarily involved conduct predating Sarah London's appointment as CEO, the settlement illustrates ongoing regulatory exposure affecting the organization.

# Section 5

## Financial Forecasting Failure

One of the defining events of Sarah London's leadership occurred during 2025 when Centene unexpectedly withdrew previously issued earnings guidance.

The company disclosed significant changes involving:

• Marketplace member health risk
• Medical expense projections
• Risk adjustment revenue
• Affordable Care Act enrollment assumptions

The resulting revision represented approximately a $1.8 billion impact.

Investors responded immediately.

Centene experienced one of the largest single-day declines in company history.

Billions of dollars in market value were erased.

The company later reported its first adjusted quarterly loss in more than a decade.

This event prompted serious questions regarding:

• Financial forecasting
• Executive oversight
• Internal reporting systems
• Actuarial assumptions
• Board supervision

# Section 6

## Shareholder Litigation

Following the withdrawal of guidance, multiple shareholder lawsuits were filed against Centene and senior executives.

The complaints generally allege that investors received overly optimistic information regarding:

• Financial outlook
• Marketplace performance
• Medical costs
• Revenue expectations

These allegations remain pending.

No court has determined liability.

Nevertheless, the litigation reflects a significant loss of investor confidence.

# Section 7

## Executive Compensation

Sarah London's publicly disclosed compensation has remained approximately $20 million annually.

Supporters argue that executive compensation reflects the complexity of managing one of America's largest healthcare organizations.

Critics note that this compensation coincided with:

• Stock price declines
• Workforce reductions
• Regulatory settlements
• Financial forecasting failures
• Organizational restructuring

The issue is not whether executive compensation is legally permissible.

The issue is whether executive pay appropriately reflects organizational performance and accountability.

# Section 8

## Workforce Reductions and Outsourcing

Centene has pursued substantial organizational restructuring.

Reported actions include:

• Workforce reductions
• Voluntary separation programs
• Office consolidations
• Divestitures
• Increased automation
• Expanded outsourcing

Reports also indicate that Centene entered into a technology agreement with Cognizant valued at more than $500 million and potentially approaching $1 billion.

The reported initiative emphasizes:

• Artificial intelligence
• Claims automation
• Customer service modernization
• Administrative efficiencies

Critics argue that simultaneous workforce reductions and increased outsourcing may negatively affect employee morale, institutional knowledge, and organizational stability.

# Section 9

## Leadership Accountability

Sarah London inherited many of Centene's legacy legal matters.

However, executive leadership ultimately bears responsibility for:

• Organizational culture
• Financial controls
• Regulatory compliance
• Strategic direction
• Public accountability

To date, there is no public evidence that Sarah London personally engaged in fraud or criminal misconduct.

The primary questions concern executive judgment, governance, operational oversight, and corporate performance rather than personal wrongdoing.

# Preliminary Conclusions

Based upon publicly available information, several recurring themes emerge.

1. Repeated Regulatory Exposure

Numerous settlements across multiple states suggest systemic compliance challenges rather than isolated disputes.

2. Financial Governance Concerns

The 2025 withdrawal of earnings guidance represents one of the most significant operational failures in recent company history.

3. Increasing Public Accountability

Because Centene receives substantial taxpayer funding, operational failures have implications extending beyond shareholders to state governments, beneficiaries, and taxpayers.

4. Leadership Performance

Sarah London's tenure has coincided with significant restructuring, operational modernization, and continuing legal challenges. Whether these actions ultimately strengthen the organization remains an open question that will be judged by future financial performance, regulatory compliance, and restored investor confidence.

## Areas Warranting Additional Review

Future investigation could examine:

• Board oversight of pharmacy benefit management practices.
• Internal audit findings before major settlements.
• Executive incentive compensation tied to quality, compliance, and financial performance.
• The impact of outsourcing and artificial intelligence on claims accuracy and member services.
• The adequacy of forecasting controls preceding the 2025 guidance withdrawal.
• Trends in state regulatory actions, corrective action plans, and sanctions involving Centene subsidiaries.
• Corporate governance practices compared with peer managed care organizations.

I have 2 serious questions.

1. Did that Wyclef Jean song ever gain any traction? LMAO
2. Is that Diddy guy still an executive at the company?
   I can’t believe I’m asking this of our once semi-respectable company.

Does anyone else find the latest LinkedIn posts by MSD endorsing some expensive gadget to combat High Blood pressure to be in poor taste ?? Dells Leadership team are probably responsible for the highest BP and anxiety levels in the industry with the toxic culture and daily threat of losing your livelihood ! Over 50,000 former Dell employees have had their lives turned upside them with no income and healthcare coverage over the past few years while Mr Dell and his narcissistic leaders continue to rake in multi million dollar paychecks !!!!

When is the board of directors and everyone else going to wake up and realize that John Stank has provided no value to the company for a long time! He is no longer relevant and if he doesn’t like the truth he can retire or find another company willing to take on an aging dinosaur. The culture under John is toxic and has been for too long.

Over the last 5 years PEP stock is down 14%.

KO stock up 43% over the same period.

That is an astounding failure. That is 100% on Ramon. The global "headwinds" were the same for both. That utterly incompetent fool of a CEO has got to go. I don't understand how Elliott Management kept him. How the PEP BoD kept him. What is going on?

I thought their reputation preceded them. I thought they cared. I thought they’d respect me and the quality of work I do day in day out with much overtime. I thought they offered respect
So far I’m finding I was duped by this persons.
I feel like they don't give a rats behind about me, my qualifications, my skills I’m just a number.
Something shifted maybe HR co-opted Abby with their lies and divisive mentality of the dei legion. But they aren’t looking to promote or help or encourage solid employees. Very disappointed.

I see the market was up again today, and the OpenText price ... oh, crud ... down again.

This company's outlook is bleak as long as Jenkins, his pupppet CEO, the so-called Board of Directors, Bell, Muhi, Rai, Berry, Cione, Acedo, and all the other Jenkins minions are in charge.

As a stockholder I demand change!

Why, as a leader in the field, am I now having to do the work of this team? The math is strange - I generate revenue, the firm allocates my revenue for this home office work yet I’m the one doing their work. From what I hear - the GP running it is inadequate and the directors are incompetent and have created a toxic environment where their staff left their area leaving us to do their roles. How are they still employed?

Gotta love the fact they are so worried about reducing costs other than top executives pay and advertising. They are main advertisers on the World Cup .. the Super Bowl … ALL THE BIG EVENTS .
It’s just an attack on the workforce to fatten that axxhats pockets

In the past 6 months many people have been laid off, including some of our best leaders. We’re seriously understaffed now. Also, there is NO investment in this business and our IT portfolio has been cut to the bone. I never hear Sean C. even talk about Dental and he doesn’t seem to meet with Dental team members. I’m not even sure who’s really in charge now. There are no signs of real leadership anymore and the communication is terrible.

This used to be a great, highly profitable business with great employees. But it’s a pathetic shell of that now. This all makes me wonder if it is being stripped down in preparation for being sold, like IFP, Medicare and (soon) EviCore. Am I missing something?

Joel didn't say anything meaniful, I had looked forward so much to that townhall like it was the Oscar's, it was just a waste if 1hr, couldn't answer any question straightforward or plainly

That means a huge LR

“An apologist is someone who writes or speaks to defend and justify a specific belief, cause, or institution, especially one that faces criticism.”

Managers need to STOP being apologists for U.S. Bank and defending bad behavior. While you’re not expected to speak ill of the company publicly , you will gain more respect of direct reports if you’re in line with reality. We can spot fakeness. Those that see U.S. Bank with rose tinted glasses are looked at with disdain. Whatever corporate carrot 🥕 you’re chasing here isn’t worth it if no one respects you at the end of the day.

Long article on FB in terms of his past at JPM and FD/Fiserv
I tend to believe the accusations and love the fact he’s the lead story that brings up his past selfish and unprofessional activities. Spying, clawing his way up the ladder, seems like a real tool

Hope in one hand and relieve yourself in the other and see which one fills up first.

And repeat the mantra "I am a close personal friend of John Donovan".